echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The first self-developed inflammatory immune drug!

    The first self-developed inflammatory immune drug!

    • Last Update: 2022-02-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Cube Info

    Author: sunshine

    On December 8, the CDE official website showed that the application for the clinical trial of BeiGene’s TYK2 allosteric inhibitor BGB-23339 was accepted


    Tyrosine kinase 2 (TYK2), a member of the JAK kinase family, functions as a key regulator of cytokine signaling pathways in a variety of immune-mediated diseases


    BGB-23339 is a potent, highly selective, investigational TYK2 allosteric inhibitor currently in clinical development, targeting the regulatory pseudokinase (JH2) domain of TYK2


    Many domestic and foreign pharmaceutical companies have already started to deploy TYK2 targets


    BMS’s emphasis on TYK2 targets is obvious.


    Domestic Nuocheng Jianhua, BeiGene, Haisco, and Microchip also have TYK2 targeted drugs under development


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.